Workflow
olomorasib
icon
Search documents
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers
Prnewswire· 2025-09-04 10:45
Core Insights - The FDA has granted Breakthrough Therapy designation to olomorasib in combination with KEYTRUDA for first-line treatment of unresectable advanced or metastatic NSCLC with KRAS G12C mutation and PD-L1 expression ≥ 50% [1][3] - Olomorasib is a second-generation KRAS G12C inhibitor showing preliminary CNS activity and is being studied in various treatment settings [1][10] Group 1: Breakthrough Therapy Designation - The Breakthrough Therapy designation aims to expedite the development and review of drugs that show substantial improvement over existing therapies for serious conditions [2] - The designation for olomorasib is based on encouraging results from the Phase 1/2 LOXO-RAS-20001 trial and the Phase 3 SUNRAY-01 trial [3][9] Group 2: Upcoming Presentations - Updated efficacy and safety data for olomorasib will be presented at the IASLC 2025 World Conference on Lung Cancer, with two oral presentations scheduled [4][5] - The first presentation will focus on the combination of olomorasib and pembrolizumab as first-line treatment in KRAS G12C-mutant NSCLC [4] - The second presentation will cover the combination of olomorasib with chemoimmunotherapy as a first-line treatment [5] Group 3: Clinical Trials - LOXO-RAS-20001 is an open-label, multicenter Phase 1/2 study evaluating olomorasib in patients with KRAS G12C-mutant advanced solid tumors [7][8] - SUNRAY-01 is a Phase 3 study comparing olomorasib plus standard therapies against placebo plus standard therapies in KRAS G12C-mutant metastatic NSCLC [9] Group 4: About Olomorasib - Olomorasib (LY3537982) is a potent and selective second-generation KRAS G12C inhibitor, with KRAS G12C mutations occurring in approximately 13% of NSCLC patients [10] - The drug is being studied in various combinations for treating advanced NSCLC and other solid tumors [10]
Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Prnewswire· 2025-05-22 21:05
Core Insights - Eli Lilly and Company is set to present data on several investigational drugs at the 2025 ASCO Annual Meeting, including imlunestrant, olomorasib, LY4170156, and Verzenio [1] Group 1: Imlunestrant (Investigational Oral SERD) - The company will present patient-reported outcomes from the Phase 3 EMBER-3 trial for patients with ER+, HER2- advanced breast cancer [2] - Expanded safety analyses from the EMBER-3 trial will also be featured in a poster presentation [2] Group 2: Olomorasib (Investigational KRAS G12C Inhibitor) - Updated results from a Phase 1/2 study of olomorasib will be reported, showing preliminary evidence of CNS activity in combination with pembrolizumab for KRAS G12C-mutant advanced NSCLC and with cetuximab for KRAS G12C-mutant colorectal cancer [3] - The presentations will utilize data cut-off dates of January 15, 2025, and November 13, 2024 [3] Group 3: LY4170156 (Investigational ADC Targeting FRα) - Initial results from a Phase 1a/1b study of LY4170156 in patients with platinum-resistant ovarian cancer will be presented [4] - The study involves a humanized monoclonal antibody linked to a topoisomerase I inhibitor [4] Group 4: Verzenio (Abemaciclib) - The impact of body mass index (BMI) on the efficacy and safety of Verzenio in breast cancer patients will be discussed [8] - Verzenio is an approved treatment for certain HR+, HER2- breast cancers and is available in multiple strengths [12][13]